Morningstar | Ceasing Coverage of Acrux
We plan to cease coverage of no-moat Acrux in early November 2018 to focus on better opportunities. We provide broad coverage of more than 1,500 companies across more than 90 industry groups globally and adjust our coverage as necessary based on client demand and investor interest. Acrux is a small, high-risk, no-moat company with an uncertain future. We still think onychomycosis, and the planned launch of a generic version of branded treatment Jublia, is an attractive market for the company, given the prevalence of nail bed infections in the general population and limited treatment options in the U.S. available prior to the launch of Jublia. While the recent lawsuit brought by Jublia’s owner Bausch Pharmaceuticals presents risk, we're encouraged by Acrux's solid financial position, with AUD 28.5 million in cash on hand at June 30, 2018.Acrux is a pharmaceutical company engaged in the development and commercialization of specialty and generic transdermal and topical pharmaceuticals for global markets. Co.'s topical or transdermal pharmaceutical product portfolio can be segregated into two streams - generic pharmaceutical products and specialty pharmaceutical products.
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.